OncoSil FY21 half yearly review
Filed with ASX · · 3 pages · English
Sydney, Australia–18 January 2021:OncoSil Medical Ltd (ASX: OSL) (OncoSilor theCompany) would like to provide a review of the Company’s operating activities over the first half of financial year 2021 (1H FY21). Building Organisational Capability OncoSil Medical employed Nigel Lange as President EMEA to head up the activities in the EMEA region. Nigel Lange has deep experience in interventional onc
Earlier from OncoSil Medical
- Termination of Mr Daniel Kenny as Chief Executive Officer
- OncoSil receives Swiss regulatory approval
- OncoSil achieves first commercial sale
- Positive PanCO trial update on resected cohort
- Receipt of $2.8m R&D Tax Incentive Refund
Later from OncoSil Medical
- Appointment of Chief Executive Officer
- OncoSil Investor Update
- Appendix 4C - quarterly
- OncoSil receives regulatory approval from Hong Kong
- OncoSil TGA regulatory update
Follow OncoSil Medical into a list and get an email when it puts out news.
Follow OncoSil Medical